In just concluded meeting of Board of Directors , the Board approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the quarter ....

Negative operating cash flowDebt to equity above the thresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.8%Reaction day

₹15.81

prior close

₹15.76

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-5.4% vs market

Pharmaceuticals peers, median of 157sector+0.1%-4.9% vs sector

On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 4.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.5

10m

+2.0

15m

+2.0

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.8+0.6-5.4+0.1-4.9

Next day

-7.7-0.2-7.4-0.7-7.0

-7.8-0.4-7.5-1.1-6.8

-8.9-0.7-8.2-0.9-8.1

-13.7-2.2-11.4-1.9-11.7

-13.3-2.8-10.5-3.1-10.2

-13.6-1.4-12.2-2.1-11.5

15d

-17.8-7.0-10.8-4.7-13.1

-19.5-6.1-13.4-5.0-14.4

-17.7-9.2-8.5-7.6-10.1

-24.9-6.8-18.0-9.5-15.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gennex Laboratories reported unaudited Q2 FY26 standalone revenue from operations of Rs. 2,932.63 lakhs, up about 18.8% from Rs. 2,468.59 lakhs in Q2 FY25. Standalone net profit grew to Rs. 453.32 lakhs from Rs. 415.85 lakhs (~9% YoY). Half-year standalone revenue rose ~19.4% to Rs. 5,496.63 lakhs, while net profit was Rs. 868.27 lakhs vs Rs. 832.45 lakhs (~4.3% YoY). On a consolidated basis, Q2 revenue was Rs. 3,724.21 lakhs (up ~18%) with net profit of Rs. 551.15 lakhs; H1 consolidated revenue was Rs. 7,141.96 lakhs with net profit of Rs. 1,052.80 lakhs. EPS stood at Rs. 0.187 (standalone) and Rs. 0.207 (consolidated) for the quarter. The auditor (R Pugalia & Co.) issued a limited review report stating nothing came to their attention requiring disclosure under Listing Regulations. The company manufactures bulk drugs (Guaifenesin, Methocarbamol) and exports to countries including Vietnam, India, Colombia, Egypt, and others.

Likely market impact

Revenue growth of ~18-19% is healthy but operating cash flow turned sharply negative (standalone -Rs. 4,628 lakhs, consolidated -Rs. 8,416 lakhs) and borrowings rose meaningfully, so profitability and cash quality remain concerns for shareholders despite top-line momentum.